Browse our anti-TNFRSF10B (TNFRSF10B) Antibodies

Full name:
anti-Tumor Necrosis Factor Receptor Superfamily, Member 10b Antibodies (TNFRSF10B)
On www.antibodies-online.com are 373 Tumor Necrosis Factor Receptor Superfamily, Member 10b (TNFRSF10B) Antibodies from 36 different suppliers available. Additionally we are shipping TNFRSF10B Proteins (47) and TNFRSF10B Kits (14) and many more products for this protein. A total of 454 TNFRSF10B products are currently listed.
Synonyms:
CD262, DR5, KILLER, KILLER/DR5, Ly98, MK, TNFRSF10B, TRAIL-R2, TRAILR2, TRICK2, TRICK2A, TRICK2B, TRICKB, xDR-M1, xDR-M2, ZTNFR9
list all antibodies Gene Name GeneID UniProt
TNFRSF10B 364420  
TNFRSF10B 8795 O14763
TNFRSF10B 21933 Q9QZM4

Show all species

Show all synonyms

Most Popular Reactivities for anti-TNFRSF10B (TNFRSF10B) Antibodies

Select your species and application

anti-Rat (Rattus) TNFRSF10B Antibodies:

anti-Human TNFRSF10B Antibodies:

anti-Mouse (Murine) TNFRSF10B Antibodies:

All available anti-TNFRSF10B Antibodies

Go to our pre-filtered search.

Top referenced anti-TNFRSF10B Antibodies

  1. Human Monoclonal TNFRSF10B Primary Antibody for FACS - ABIN4898055 : Peppa, Gill, Reynolds, Easom, Pallett, Schurich, Micco, Nebbia, Singh, Adams, Kennedy, Maini: Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. in The Journal of experimental medicine 2013 (PubMed)
    Show all 13 references for 4898055

  2. Mouse (Murine) Polyclonal TNFRSF10B Primary Antibody for FACS, Neut - ABIN4900408 : Park, Wu, Choi, Najafi, Emami, Safa: P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. in Biochemical pharmacology 2006 (PubMed)
    Show all 3 references for 4900408

  3. Human Monoclonal TNFRSF10B Primary Antibody for FACS - ABIN1106166 : Mérino, Lalaoui, Morizot, Schneider, Solary, Micheau: Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. in Molecular and cellular biology 2006 (PubMed)
    Show all 2 references for 1106166

  4. Human Monoclonal TNFRSF10B Primary Antibody for FACS - ABIN238400 : Corallini, Milani, Nicolin, Secchiero: TRAIL, caspases and maturation of normal and leukemic myeloid precursors. in Leukemia & lymphoma 2006 (PubMed)

  5. Human Polyclonal TNFRSF10B Primary Antibody for WB - ABIN2792103 : Baritaki, Suzuki, Umezawa, Spandidos, Berenson, Daniels, Penichet, Jazirehi, Palladino, Bonavida: Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. in Journal of immunology (Baltimore, Md. : 1950) 2008 (PubMed)

  6. Human Polyclonal TNFRSF10B Primary Antibody for WB - ABIN222914 : Erster, Mihara, Kim, Petrenko, Moll: In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. in Molecular and cellular biology 2004 (PubMed)

More Antibodies against TNFRSF10B Interaction Partners

Human Tumor Necrosis Factor Receptor Superfamily, Member 10b (TNFRSF10B) interaction partners

  1. Study provides direct biophysical evidence that Death Receptor 5 disulfide-linked transmembrane (TM)-dimers open in response to ligand binding. Then, to probe the importance of the closed-to-open TM domain transition in the overall energetics of receptor activation, point-mutants (alanine to phenylalanine) in the predicted, tightly packed TM domain dimer interface were designed and tested.

  2. High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer cells and xenograft tumors.

  3. Oridonin analog CYD (show CYBB Antibodies)-6-28 induces apoptosis at least partially by inducing the expression of death receptor 5 in breast neoplasms.

  4. The authors show that cholesterol is necessary for the covalent dimerization of DR5 transmembrane domains.

  5. Mono treatment with lexatumumab was not sufficient to induce apoptosis in pancreatic cancer cells, whereas focal adhesion kinase inhibitor PF573228 significantly sensitized lexatumumab-induced apoptosis. Western blotting analysis revealed that lexatumumab and PF573228 combination treatment increased death receptor 5 but decreased Bcl-xL (show BCL2L1 Antibodies) expression.

  6. We demonstrate that PBOX-15 can enhance TRAIL-induced apoptosis by upregulation of DR5, reduction of cellular mitochondrial potential, activation of the caspase (show CASP3 Antibodies) cascade and downregulation of PI3K (show PIK3CA Antibodies)/Akt (show AKT1 Antibodies), c-FLIP (show CFLAR Antibodies), Mcl-1 (show MCL1 Antibodies) and IAP (show ALPI Antibodies) survival pathways

  7. The nanovectorization of TRAIL enhanced its binding to both DR4 (show HLADRB4 Antibodies) and DR5 receptors at 37 degrees C and could potentially sensitized cancer cells to TRAIL induced apoptosis through simultaneous activation of DR4 (show HLADRB4 Antibodies) and DR5 as described in this paper for the non-small lung carcinoma cell line (H1703), the two hepatocarcinoma cell lines (SK-Hep1, HUH) and the colon carcinoma cell line (HCT116WT).

  8. we found that CQ decreased the expression of Cbl (show CBL Antibodies), an E3 ligase of DR5, and knock-down of Cbl (show CBL Antibodies) markedly enhanced DR5 up-regulation. Other lysosomal inhibitors, including monensin and nigericin, also up-regulated DR5 and sensitized TRAIL-mediated apoptosis

  9. MG132 possesses anti-gallbladder cancer potential that correlate with regulation of DR5-dependent pathway.

  10. Edelfosine also activated p38MAPK (MAPK14 (show MAPK14 Antibodies)), and edelfosine-mediated rhTRAIL sensitization was partially regulated by a p38 (show CRK Antibodies)-mediated decrease in mitochondrial membrane potential. This study suggests a novel therapeutic strategy targeting gastric cancer cells by using the combination of edelfosine and TRAIL.

Mouse (Murine) Tumor Necrosis Factor Receptor Superfamily, Member 10b (TNFRSF10B) interaction partners

  1. Authors demonstrate, for the first time, expression of TNF-related apoptosis-inducing ligand (TRAIL (show TNFSF10 Antibodies)) and its signaling death receptor 5 (DR5) in the murine inner ear.

  2. Malignant transformation in the endometrium is related to reduction of membrane DR4 (show HLADRB4 Antibodies) and DR5 expression.

  3. TRAIL expression by osteoclast-like cells is increased in the presence of RANKL (show TNFSF11 Antibodies) and after scraping; DcR2 (show TNFRSF10D Antibodies) expression peaks at 24 hours, and and decreases at 5 days; DR5 expression peaks at 5 days

  4. Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34 (show CD34 Antibodies)(+) cells.

  5. TRAIL-DR5 interaction promoted malignant behaviors of B16F10 cells.

  6. results suggest that the transmembrane domains together with their adjacent stalk regions can play a major role in control of death receptor activation thereby contributing to cell type specific differences in TRAILR1 and TRAILR2 signaling

  7. DR5 is selectively expressed by neuroprogenitor cells and newborn neurons.

  8. Results suggest that excessive iodine could induce TRAIL and DR5 abnormal expression in thyroid. TRAIL band with DR5 to promote follicular cells apoptosis thus mediate thyroid destruction in EAT.

  9. NK cells inhibit dendritic cell cross-priming, but not direct priming, in a TRAIL/DR5-dependent manner.

  10. Antibody-based therapy targeting DR5 is an efficient strategy not only to eliminate TRAIL-sensitive tumor cells.

TNFRSF10B Antigen Profile

Antigen Summary

The protein encoded by this gene is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. Two transcript variants encoding different isoforms and one non-coding transcript have been found for this gene.

Alternative names and synonyms associated with TNFRSF10B

  • tumor necrosis factor receptor superfamily, member 10b (Tnfrsf10b) antibody
  • tumor necrosis factor receptor superfamily, member 10b (TNFRSF10B) antibody
  • tumor necrosis factor receptor superfamily, member 10b (tnfrsf10b-b) antibody
  • tumor necrosis factor receptor superfamily, member 10b (tnfrsf10b) antibody
  • CD262 antibody
  • DR5 antibody
  • KILLER antibody
  • KILLER/DR5 antibody
  • Ly98 antibody
  • MK antibody
  • TNFRSF10B antibody
  • TRAIL-R2 antibody
  • TRAILR2 antibody
  • TRICK2 antibody
  • TRICK2A antibody
  • TRICK2B antibody
  • TRICKB antibody
  • xDR-M1 antibody
  • xDR-M2 antibody
  • ZTNFR9 antibody

Protein level used designations for TNFRSF10B

tumor necrosis factor receptor superfamily, member 10b , death receptor-M2 , death receptor-M1 , Fas-like protein , TNF-related apoptosis-inducing ligand receptor 2 , apoptosis inducing protein TRICK2A/2B , apoptosis inducing receptor TRAIL-R2 , cytotoxic TRAIL receptor-2 , death domain containing receptor for TRAIL/Apo-2L , death receptor 5 , p53-regulated DNA damage-inducible cell death receptor(killer) , tumor necrosis factor receptor superfamily member 10B , tumor necrosis factor receptor-like protein ZTNFR9 , KILLER/DR5 TRAIL death-inducing receptor

GENE ID SPECIES
364420 Rattus norvegicus
282533 Bos taurus
404687 Xenopus laevis
404688 Xenopus laevis
448240 Xenopus (Silurana) tropicalis
742898 Pan troglodytes
8795 Homo sapiens
21933 Mus musculus
Selected quality suppliers for anti-TNFRSF10B (TNFRSF10B) Antibodies
Did you look for something else?